ESR1 and breast carcinoma: The phase II ELAINE-1 trial was conducted in HR+/HER2− relapsed breast cancer, with 40% of the subjects having the Y537S ESR1 mutation and progressing on prior AI and CDK4/6is; lasofoxifene was given as a single agent against fulvestrant and did not significantly prolong PFS [159].